← All trials
NCT03788837
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 17, 2019
- Primary completion
- Apr 15, 2021
- Completion date
- Apr 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 236
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Assistance Publique - Hôpitaux de ParisStudy director
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.